BETA
Your AI-Trained Oncology Knowledge Connection!
Lenvatinib Combo Improves Clinical Benefit in Clear Cell RCC Subgroups
Additionally, PFS data in the CLEAR trial confirm the benefit of the lenvatinib combination in patients with clear cell RCC regardless of PD-L1 IHC.
HK2-Targeting Radioligand Shows Responses With Some AEs in Metastatic CRPC
Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.
Pembrolizumab Combo Yields Efficacy in Penile Squamous Cell Carcinoma
Pembrolizumab plus platinum-containing therapy may be a new treatment option for advanced penile cancer based on data from the HERCULES trial.
Daratumumab Combo Yields MRD-Negative Status in Transplant-Eligible Myeloma
Data from the PERSEUS trial also show that responses deepened over time in both arms among patients with transplant-eligible multiple myeloma.
Novel PROTAC Androgen Receptor Elicits Clinical Activity in Metastatic CRPC
Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.
Leveraging “Exciting” CAR T-Cell Therapy Advancements in Multiple Myeloma
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Early Efficacy Observed With Teclistamab Combo in Newly Diagnosed Myeloma
Most infection events among those with newly diagnosed multiple myeloma in the MajesTEC-7 trial appeared to occur early during study treatment.
Prolonged PFS Observed in Isatuximab Combo in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Isatuximab, bortezomib, lenalidomide, and dexamethasone prolonged PFS vs bortezomib, lenalidomide, and dexamethasone, in a subsect of patients with multiple myeloma.
Building On Outcomes With Isatuximab in Newly Diagnosed Myeloma
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Clinical CRs Seen in Entire Dostarlimab dMMR Rectal Cancer Cohort
No patients with dMMR rectal cancer enrolled on a phase 2 study required subsequent chemotherapy or radiation following treatment with dostarlimab.
EFS Improvement Observed With Perioperative Nivolumab in Stage III N2/non-N2 NSCLC
CheckMate 77T trial saw an EFS improvement with neoadjuvant nivolumab in stage III N2 and stage III non-N2 non–small cell lung cancer.
Intracranial Control Seen With Dato-DXd in NSCLC Brain Metastasis Subgroups
Phase 2 data support further evaluation of datopotamab deruxtecan in patients with non–small cell lung cancer and brain metastases.
MAIC Study Finds Similar Results With Linvoseltamab/Teclistamab in R/R Multiple Myeloma
Similar outcomes were noted when linvoseltamab and teclistamab were analyzed as treatments for patients with relapsed/refractory multiple myeloma.
Durable EFS Noted in Nivolumab/Chemo in Resectable NSCLC
The CheckMate 816 trial reinforced the EFS data of nivolumab plus chemotherapy in resectable NSCLC.
EV-302 PRO Outcomes Find Consistent Efficacy Data in Urothelial Carcinoma
Patient-reported outcomes from the EV-302 trial found consistent efficacy and safety outcomes for patients with urothelial carcinoma.
Adjuvant Atezolizumab Sustains Survival Vs BSC in Stage IB to IIIA NSCLC
Final DFS results from IMpower010 show consistent survival when adjuvant atezolizumab was used in stage IB to IIIA NSCLC.
Time to Progression in mHSPC Cohort Prolonged With Darolutamide
The rate of subsequent anticancer therapy was reduced with darolutamide vs placebo in patients with mHSPC in the ARASENS trial.
Envafolimab Combo Yields Enduring Responses in Advanced Endometrial Cancer
Data support subcutaneous envafolimab plus lenvatinib as a promising new therapy option in advanced endometrial cancer.
Circulating KIM-1 May Predict Benefit With Atezolizumab in RCC
KIM-1 was the most significantly enriched circulating protein in recurrence vs baseline serum samples among patients in the IMmotion010 trial.
Extending the Benefits of Avelumab Maintenance in Urothelial Carcinoma
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Talquetamab Yields Responses in Pre-Treated R/R Multiple Myeloma
Data suggest that those with relapsed/refractory multiple myeloma and poor functional status may benefit from talquetamab without increased toxicity.
Predicting Responses to Sacituzumab Govitecan Combo in Urothelial Cancer
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
QOL Data Support Belantamab Mafodotin Combo in R/R Multiple Myeloma
Eye-related adverse effects after treatment for relapsed/refractory multiple myeloma in DREAMM-7 appear manageable with dose and schedule changes.
Step-Up Teclistamab Dosing Produces Responses in R/R Multiple Myeloma
Giving tocilizumab before step-up dosing of teclistamab may mitigate cytokine release syndrome in relapsed/refractory multiple myeloma.
Multi-Peptide Vaccine Combo Shows Tolerability in Metastatic MSS CRC
Phase 2 data show that vaccination with PolyPEPI1018 may enhance the efficacy of atezolizumab in those with microsatellite stable metastatic CRC.
Daratumumab Retreatment Yields Sustained Response in R/R Multiple Myeloma
Responses occurred in patients with relapsed/refractory multiple myeloma who are refractory to daratumumab but received retreatment with the agent.
Enfortumab Vedotin Shows Activity in Cisplatin-Ineligible MIBC
Less than half of the patients enrolled on cohort H of the EV-103 trial required subsequent anticancer therapy following enfortumab vedotin.
Sacituzumab Govitecan Produces Finite Efficacy After Enfortumab Vedotin in Bladder Cancer Subsect
Limited efficacy was observed when sacituzumab govitecan was given after enfortumab vedodin in metastatic urothelial carcinoma.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Camrelizumab Combo Improves PFS/OS Vs Sorafenib in Advanced HCC
The median progression-free survival and overall survival was extended with rivoceranib among those with unresectable HCC in the CARES-310 trial.
